NCT07498504 is a clinical trial in Long COVID, sponsored by NYU Langone Health.

Who is sponsoring NCT07498504?

NCT07498504 is sponsored by NYU Langone Health.

What condition does NCT07498504 study?

NCT07498504 studies Long COVID, Long Covid19.

Is NCT07498504 still recruiting?

NCT07498504 is currently not yet recruiting. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT07498504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RECOVER-Adult Cycle 2: A Long-Term Follow Up Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults

Not yet recruiting Last updated 23 March 2026

What this trial tests

trial in Long COVID in 5,205 participants. Not yet recruiting.

Timeline

1 May 2026

Primary endpoint
1 April 2030

1 April 2030

Quick facts

Lead sponsor	NYU Langone Health
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	5,205
Start date	1 May 2026
Primary completion	1 April 2030
Estimated completion	1 April 2030
Sites	1 location across United States

Conditions studied

Long COVID — all drugs for Long COVID →
Long Covid19 — all drugs for Long Covid19 →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 18 to 100, any sex, with Long COVID or Long Covid19. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Long COVID Research Index (LCRI) Score of 11 or Higher
Time frame: Baseline, Month 6, Month 12, Month 18, Month 24
The LCRI 11 assesses symptoms such as malaise, brain fog, and fatigue to classify individuals into likely LC, possible LC, or no LC. A score of 11 or greater indicates high-symptom cases of LC.
Percentage of Participants with LC Remission
Time frame: Month 6, Month 12, Month 18, Month 24
Percentage of participants who experience remission from LC.
Percentage of Participants with New Onset Conditions
Time frame: Month 6, Month 12, Month 18, Month 24
New onset conditions include, but are not limited to, dementia, coronary artery disease, diabetes, renal disease, cancer, and myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

Sponsor's own description

Long COVID (LC) affects an estimated 5-10% of individuals with SARS-CoV-2 causing a persistent physical, cognitive, and functional impairment with potentially severe socioeconomic consequences. While RECOVER-Adult cycle 1 established the largest, most comprehensive U.S. adult LC cohort (14,730 participants), key questions remain about long-term disease trajectories, biological mechanisms, and late-emerging complications. RECOVER-Adult cycle 2 will follow selected participants for two years each, focusing on neurocognitive, cardiopulmonary and infection-associated chronic conditions (IACC) such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and autonomic dysfunction. Using a case-cohort design, the study will investigate disease persistence versus resolution, biological mechanisms, and onset of new chronic illnesses, generating critical insights to guide prevention, treatment, and public health policy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Long COVID

Currently open trials in the same condition.

NCT05931497 — Sauna for Long Covid · NA · recruiting
NCT06452095 — Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy fo · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
NCT07435805 — Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation · recruiting
NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07498504 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07498504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing